Bausch Health (BHC) Canada said Wednesday its Cabtreo treatment for acne vulgaris has been made available to beneficiaries of the public drug plans of Ontario and Nova Scotia.
The treatment is also available through the Candian government's Non-Insured Health Benefits drug plan for Indigenous populations and through the Correctional Service of Canada, the company said.
Bausch Health Canada General Manager Amy Cairns said the company plans to complete listing arrangements with other public drug plans in Canada "in the near future."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.